4//SEC Filing
Valeant Pharmaceuticals International, Inc. 4
Accession 0000885590-15-000029
$BHCCIK 0000885590operating
Filed
Apr 27, 8:00 PM ET
Accepted
Apr 28, 4:38 PM ET
Size
11.2 KB
Accession
0000885590-15-000029
Insider Transaction Report
Form 4
Schiller Howard Bradley
EVP and CFO
Transactions
- Exercise/Conversion
Common Stock, no par value
2015-04-27+22,500→ 306,007 total - Exercise/Conversion
Restricted Share Units
2015-04-27−22,500→ 0 total→ Common Stock (22,500 underlying) - Tax Payment
Common Stock, no par value
2015-04-27−11,779→ 294,228 total - Tax Payment
Common Stock, no par value
2015-04-27−4,859→ 289,369 total
Footnotes (4)
- [F1]Each performance-based Restricted Share Unit ("PSU") represents a contingent right to receive between zero and three common shares, no par value ("Common Shares"), of Valeant Pharmaceuticals International, Inc. ("Valeant"), subject to performance based vesting criteria. See note (2).
- [F2]These RSUs were initially eligible to vest based on total shareholder return ("TSR") between a price of $42.70 starting on December 1, 2011 and the average stock price for the 20 trading days starting on each measurement dates: 25% on September 1, 2014, 50% on December 1, 2014 and 25% on March 1, 2015, contingent on TSR performance between 15% and 45% into between one and three Common Shares of common stock, respectively, with early vesting possible at higher TSR levels. These PSUs have now vested in full.
- [F3]This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of PSUs.
- [F4]This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Matching Restricted Share Units.
Documents
Issuer
Valeant Pharmaceuticals International, Inc.
CIK 0000885590
Entity typeoperating
IncorporatedNJ
Related Parties
1- filerCIK 0000885590
Filing Metadata
- Form type
- 4
- Filed
- Apr 27, 8:00 PM ET
- Accepted
- Apr 28, 4:38 PM ET
- Size
- 11.2 KB